Our Experience
Jonas Molecular has over 30 years of infectious disease molecular diagnostics experience and has been involved in all aspects of IVD product development from implementing product development processes, establishing product requirements, assay verification, and validation and product launch.
Jonas Molecular can assist in facilitating communication between assay developers and engineers so that the right product is launched.
Using their extensive knowledge in molecular diagnostics and applying it to the global health market, Jonas Molecular has been able to advise companies on how to develop and position products so that they can be marketed and distributed worldwide.
Jonas Molecular has the necessary experience in understanding market needs and translating those needs into the appropriate Product Requirements and Specifications that will enable companies to make products that, not only perform well, but are exactly what customers want.
“I became acquainted with Vivian 30 years ago when working at the Wadsworth Center of the New York State Department of Health and collaborated with her on a research study on molecular identification of M. tuberculosis.
Vivian is a highly qualified expert in laboratory diagnosis of infectious diseases and public health. I was always impressed by her broad experience in laboratory science, which encompasses product development, clinical validation and evaluation, regulatory authorization, field implementation, and quality assurance of molecular diagnostics. Due to her unique skill set I would sincerely and strongly recommend to rely on her guidance in any complex laboratory science related subject.”
– Akos Somoskovi, M.D., Ph.D. Director of Clinical Science, Roche Molecular Systems
Principal Leadership
Vivian Jonas-Taggart
Vivian has over 30 years of infectious disease molecular diagnostics experience working for companies like Gen-Probe, Hologic, and Erba Molecular. She has a proven record of developing, launching, and supporting molecular diagnostic products with an emphasis on mycobacteria. She received USFDA approval on ten products including the first amplified assay for the detection of tuberculosis and has two issued patents. Her thorough understanding of customer needs from the molecular clinical diagnostics standpoint, as well as her appreciation of the global nature of the molecular diagnostics market and understanding of the regulatory and business implications in different geographies, gives her a unique perspective on product development.